Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19

  • STATUS
    Recruiting
  • End date
    Sep 30, 2021
  • participants needed
    100
  • sponsor
    Rabin Medical Center
Updated on 25 March 2021
diabetes
insulin
diabetes mellitus
type 2 diabetes mellitus
covid-19
SARS
pulmonary disease
glycoprotein
type 1 diabetes mellitus
angiotensin converting enzyme
coronavirus infection
dipeptidyl peptidase-4 inhibitor
linagliptin
linagliptin 5 mg

Summary

The coronavirus disease 2019 (COVID-19) is an emerging pandemic in 2020 caused by a novel coronavirus named SARS-CoV2. Diabetes confers a significant additional risk for COVID-19 patients. Dipeptidyl peptidase 4 (DPP-4) is a transmembrane glycoprotein expressed ubiquitously in many tissues. In addition to its effect on glucose levels, DPP-4 has various effects on the immune system and several diseases, including lung diseases. This trial aims to assess the safety and efficacy of linagliptin, a DPP-4 inhibitor, in the treatment of COVID-19. The trial will be randomized without blinding, with one are treated by insulin only for glucose balance and the other by insulin and linagliptin. The trial will assess the effects of linagliptin on different measures of COVID-19 recovery.

Details
Condition Endocrine disorder, Coronavirus Infection, Metabolic disorder, Incretins, NIDDM, Diabetes Mellitus, Dipeptidyl-Peptidase IV Inhibitors, Respiratory Tract Diseases, antidiabetic agent, Glucose Metabolism Disorders, Hormone, Coronavirus, Diabetes Mellitus, Type 2, Diabetes Prevention, Diabetes Mellitus Types I and II, Diabetes (Pediatric), Metabolic Disorders, Diabetes Mellitus Type 2, *COVID-19, Covid-19, Severe Acute Respiratory Syndrome Coronavirus 2, Linagliptin, Sars-CoV2, Sars-CoV2, type 2 diabetes mellitus, hormone agent, incretin, incretin hormone, hypoglycaemic agent, hypoglycaemic, antihyperglycemic, hypoglycemic agents, hypoglycemic drugs, hypoglycemic, hypoglycemic agent, diabetes mellitus (dm), metabolic diseases, metabolic disease, metabolism disorders, respiratory tract disease, type 2 diabetes, type ii diabetes, noninsulin-dependent diabetes mellitus, diabetes type 2, endocrinopathy, endocrine disorders, endocrine disease, endocrine diseases, SARS COV2
Treatment Linagliptin 5 MG
Clinical Study IdentifierNCT04371978
SponsorRabin Medical Center
Last Modified on25 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: Diabetes Mellitus Types I and II or Endocrine disorder or NIDDM or Metabolic Disorders or Linagliptin or Metabolic disorder or Incretins or Severe Acu...?
Do you have any of these conditions: endocrine disease or hypoglycaemic or endocrine diseases or type ii diabetes or Metabolic Disorders or Diabetes Mellitus Type 2 or Severe Acute Respir...?
Do you have any of these conditions: Hormone or hypoglycemic agents or Linagliptin or incretin or antidiabetic agent or hypoglycemic or incretin hormone or Metabolic Disorders or Diabetes...?
Do you have any of these conditions: metabolic diseases or Metabolic Disorders or Diabetes Mellitus, Type 2 or incretin or Glucose Metabolism Disorders or Severe Acute Respiratory Syndrom...?
Age 18 years
History of or type 2 diabetes mellitus or a diagnosis of type 2 diabetes during hospitalization
Confirmation of infection with SARS-CoV-2 by PCR testing
Patients within 10 days from symptom onset or patients within 48 hours after laboratory diagnosis (SARS-CoV-2 PCR)

Exclusion Criteria

WHO COVID-19 Ordinal Scale for Clinical Improvement 6
Respiratory failure requiring mechanical ventilation prior to randomization
Use of vasopressor or inotropic medications prior to randomization
Intolerance/hypersensitivity to dipeptidyl peptidase-4 inhibitors
Patients expected to require intensive care unit admission or immediate surgical intervention
Participation in another trial assessing any treatment for COVID-19
Current treatment with a DPP-4 inhibitor
Pregnancy
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note